Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: Results of a Società Italiana di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process

Transfusion

Volumn 52, Issue 4, 2012, Pages 893-905

  Pierelli, Luca ^{a,b,c,d,e,f,g,h,i,j}   Perseghin, Paolo ^{a,b,c,d,e,f,g,h,i,j}   Marchetti, Monia ^{a,b,c,d,e,f,g,h,i,j}   Accorsi, Patrizia ^{a,b,c,d,e,f,g,h,i,j}   Fanin, Renato ^{a,b,c,d,e,f,g,h,i,j}   Messina, Chiara ^{a,b,c,d,e,f,g,h,i,j}   Olivieri, Attilio ^{a,b,c,d,e,f,g,h,i,j}   Risso, Marco ^{a,b,c,d,e,f,g,h,i,j}   Salvaneschi, Laura ^{a,b,c,d,e,f,g,h,i,j}   Bosi, Alberto ^{a,b,c,d,e,f,g,h,i,j}  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c Ospedale C Massaia   (Italy)

^d Azienda Ospedaliera Santo Spirito   (Italy)

^e UNIVERSITY HOSPITAL OF UDINE   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g SAN CARLO HOSPITAL   (Italy)

^h G GASLINI INSTITUTE   (Italy)

ⁱ UNIVERSITY OF PAVIA   (Italy)

^j UNIVERSITY OF FLORENCE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CD34 SELECTION; CLINICAL PRACTICE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; HEMATOLOGIST; HUMAN; LEUKAPHERESIS; MEDICAL SOCIETY; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PHYSICIAN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL MOBILIZATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSFUSIONIST; TREATMENT INDICATION;

ADULT; BLOOD COMPONENT REMOVAL; BLOOD DONORS; CELL COUNT; CELL SEPARATION; CHILD; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84859756385     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03385.x     Document Type: Conference Paper

References (95)

1. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A, Fraundorfer K,. The EBMT activity survey 2009: trends over the past five years. Bone Marrow Transplant 2011; 46: 485-501.
2. Siddiq S, Pamphilon D, Brunskill S, Doree C, Hide C, Stanworth S,. Bone marrow harvest versus peripheral blood stem cell collection for haematopoietic stem cell donation in healthy donors. Cochrane Database Syst Rev 2009;(1):CD006406.
3. Sheridan WP, Fox RM, Begley CG, Maher D, McGrath KM, Begley CG, Juttner C, To Lik B, Szer J, Mostyn G,. Effect of peripheral blood progenitor cells mobilized by filgrastim (g-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-4.
4. Sher GD, Devine DV,. The consensus development process in transfusion medicine: does it add value? Transfusion 2007; 47: 2176-9.
5. Fischmeister G, Kurz M, Haas OA, Micksche M, Buchinger P, Printz D, Ressmann G, Stroebel T, Peters C, Fritsch G,. G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability. Ann Hematol 1999; 78: 117-23.
6. Sohn SK, Kim JG, Seo KW, Chae YS, Jung JT, Suh JS, Lee KB,. GMCSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002; 30: 81-6.
7. Lane TA, Ho AD, Bashey A, Peterson S, Young D, Law P,. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage and granulocyte-colony-stimulating factors. Transfusion 1999; 39: 39-47.
8. Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Bourquelot P, Greinix H, Frickhofen N, Ringden O, Zander A, Apperley JF, Gorin N, Borkett K, Schwab G, Goebel M, Russell NH, Gratwohl A,. Allogeneic bone marrow transplantation vs. filgrastim-mobilised peripheral progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicenter trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003.
9. Blaise D, Kuentz M, Fortanier C, Bouris JH, Milpied N, Sutton L, Jouet JP, Attal M, Bordigoni P, Cahn JY, Boiron JM, Schuller MP, Moatti JP, Michallet M,. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18: 537-46.
10. Höglund M, Smedmyr B, Bengtsson M, Tötterman TH, Cour-Chabernaud V, Yver A, Simonsson B,. Mobilization of CD34+ cells by glycosylated and nonglycosylated GCSF in healthy volunteers: a comparative study. Eur J Haematol 1997; 59: 177-83.
11. Watts MJ, Addison I, Long SG, Hartley S, Warrington S, Boyce M, Linch DC,. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 1997; 98: 474-9.
12. Hashimoto S, Itoh M, Nishimura M, Asai T,. Effect of filgrastim administration for steady-state mobilization of peripheral blood stem cells. Ther Apher 2002; 6: 431-6.
13. Kröger N, Renges H, Krüger W, Gutensohn K, Löliger C, Carrero I, Cortes L, Zander AR,. A randomized comparison of once versus twice daily r-Hu granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761-5.
14. Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ,. Peripheral blood stem cell yield in 400 normal donors mobilized with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006; 134: 517-25.
15. Kroschinsky F, Hölig K, Poppe-Thiede K, Zimmer K, Ordemann R, Blechschmidt M, Oelschlaegel U, Bornhauser M, Rall G, Rutt C, Ehninger G,. Single-dose pegfilgrastim for mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica/Hematol J 2005; 90: 1665-71.
16. Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, Devine H, Link DC, Calandra G, Bridger G, Westervelt P, DiPersio JF,. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990-8.
17. Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M, Mealiffe M, Leon LW, Terstappen LW, Hardwick A, Moubayed M, Oldham F, Corringham RE, Ho AD,. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-SCF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-82.
18. Kim SN, Moon JH, Kim JG, Cho YY, Lee SJ, Kim YJ, Lee YJ, Suh JS, Lee KS, Sohn SK,. Mobilization effects of G-CSF, GM-CSF, and darbepoetin-alpha for allogeneic peripheral blood stem cell transplantation. J Clin Apher 2009; 24: 173-9.
19. Falzetti F, Aversa F, Minelli O, Tabilio A,. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353: 555.
20. Balaguer H, Galmes A, Ventayol G, Bargay J, Besalduch J,. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004; 44: 1260-1.
21. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R, Martin PJ, Flowers ME, Storek J, Georges G, Storb R, Torok-Storb B,. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell graft affects engraftment kinetics and development of extensive chronic graft-versus-host disease after HLA-identical sibling transplantation. Blood 2001; 98: 3221-27.
22. Gorin NC, Labopin M, Boiron JM, Theorin N, Littlewood T, Shlavin S, Greinix H, Cahn JY, Alessandrino EP, Rambaldi A, Nagler A, Polge E, Rocha V,. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond-the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2006; 24: 3959-66.
23. Pulsipher MA, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP, Horowitz MM, Miller JP, King RJ, Confer DL,. Donor, recipient and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009; 114: 2606-16.
24. Champlin R, Hesdorffer C, Lowenberg B, Martelli MF, Mertelsmann RH, Reisner Y, Schmitz N,. Haploidentical "megadose" stem cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings. Leukemia 2002; 16: 427-8.
25. Koh LP, Rizzieri DA, Chao NJ,. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. Biol Blood Marrow Transplant 2007; 13: 1249-67.
26. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Smith C, Gong JZ, Lagoo A, Niedzwiecki D, Dowell JM, Waters-Pick B, Liu CX, Marshall D, Vredenburgh JJ, Gockerman J, Decastro C, Moore J, Chao NJ,. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690-7.
27. Lau GK, Lie AK, Kwong YL, Lee CK, Hou J, Lau YL, Lim WL, Liang R,. A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 2000; 96: 452-8.
28. Piekarska A, Zaucha JM, Hellmann A, McDonald GB,. Prevention of hepatitis B virus transmission from an infected stem cell donor. Bone Marrow Transplant 2007; 40: 399-40.
29. Ljungman P, Johansson N, Aschan J, Glaumann H, Lonnqvist B, Ringden O, Sparrelid E, Sonnerborg A, Winiarski J, Gahrton G,. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplantation recipients. Blood 1995; 86: 1614-8.
30. Vance EA, Soiffer RJ, McDonald GB, Myerson D, Fingeroth J, Ritz J,. Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation 1996; 62: 1358-60.
31. Hölig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH, Rutt C, Ehninger G,. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757-63.
32. Shaw BE, Ball L, Beksac M, Bengtsson M, Confer D, Diler S, Fechter M, Greinix H, Koh M, Lee S, Nicoloso-De-Faveri G, Philippe J, Pollichieni S, Pulsipher M, Schmidt A, Yang E, van Walraven AM,; Clinical Working Group; Ethics Working Group of the WMDA. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. Bone Marrow Transplant 2010; 45: 832-8.
33. Al-Ali HK, Bourgeois M, Krahl R, Edel E, Leiblein S, Poenisch W, Basara N, Lange T, Niederwieser D,. The impact of age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010 Dec 6. [Epub ahead of print]. doi: 10.1038/bmt.2010.310.
34. Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ, Champlin RE, Körbling M,. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 1999; 39: 555-60.
35. Lysák D, Kořístek Z, Gašová Z, Skoumalová I, Jindra P,. Efficacy and safety of peripheral blood stem cell collection in elderly donors; does age interfere? J Clin Apher 2011; 26: 9-16.
36. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G, Baldomero H, Niederwieser D, Apperley JF, Gratwohl A,. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94-101.
37. Díaz MA, Sevilla J, de la Rubia J, Verdeguer A, Espigado I, Vicent MG, Pascual MJ, Zamora C, Arrieta R, Serrano D, del Cañizo C, Arbona C, de Arriba F, Bargay J, Brunet S, Sanz MA,. Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation. Haematologica 2003; 88: 919-22.
38. LeBlanc R, Roy J, Vu L, Cantin G,. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant 1999; 23: 991-6.
39. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G,. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 8663: 580-5.
40. Nowrousian MR, Waschke S, Bojko P, Welt A, Schuett P, Ebeling P, Flasshove M, Moritz T, Schuette J, Seeber S,. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann Oncol 2003; 14/1: 29-36.
41. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD,. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral blood stem cells. J Clin Oncol 2000; 18: 43-53.
42. Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ,. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 395-404.
43. Kopf B, De Giorgi U, Vertogen B, Monti G, Molinari A, Turci D, Dazzi C, Leoni M, Tienghi A, Cariello A, Argnani M, Frassineti L, Scarpi E, Rosti G, Marangolo M,. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant 2006; 38: 407-12.
44. Spitzer G, Adkins D, Mathews M, Velasquez W, Bowers C, Dunphy F, Kronmueller N, Niemeyer R, McIntyre W, Petruska P,. Randomized comparison of G-CSF + GM-CSF vs. G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 1997; 20: 921-30.
45. Ataergin S, Arpaci F, Turan M, Solchaga L, Cetin T, Ozturk M, Ozet A, Komurcu S, Ozturk B,. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 2008; 83: 644-8.
46. André M, Baudoux E, Bron D, Canon JL, D'Hondt V, Fassotte MF, D'Hondt L, Fillet G, Humblet Y, Jerusalem G, Vermeulen P, Symann M, Beguin Y,. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003; 43: 50-7.
47. Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M, Fen T, Genc Y, Dincer S, Arslan O, Gürman G, Demirer S, Ozet G, Uysal A, Konuk N, Ilhan O, Koc H, Akan H,. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116: 468-74.
48. Kim S, Kim HJ, Park JS, Lee J, Chi HS, Park CJ, Huh J, Suh C,. Prospective randomized comparative observation of single- vs. split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005; 84: 742-7.
49. Ozcelik T, Topcuoglu P, Beksac M, Ozcan M, Arat M, Biyikli Z, Bakanay SM, Ilhan O, Gurman G, Arslan O, Demirer T,. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs. late administration of recombinant human G-CSF. Bone Marrow Transplant 2009; 44: 779-83.
50. de Azevedo AM, Nucci M, Maiolino A, Vigorito AC, Simões BP, Aranha FJ, Tabak DG, Voltarelli J, de Souza CA,. A randomized, multicenter study of G-CSF starting on day +1 vs. day +5 after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002; 29: 745-51.
51. Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, Baker N, Barker P, Skacel T, Schmitz N,. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93: 405-12.
52. Kobbe G, Bruns I, Fenk R, Czibere A, Haas R,. Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant 2009; 43: 669-77.
53. Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Kröger N, et al,. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2010; 46: 1045-52.
54. Bensinger W, DiPersio JF, McCarty JM,. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181-95.
55. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G,. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-73.
56. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G,. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-6.
57. Publicover A, Richardson DS, Hill K, Hurlock C, Casey YP, Newman J, Orchard KH,. Use of biosimilars GCSF for peripheral blood progenitor cell mobilisation prior to autologous stem cell transplantation: a single centre experience. 36° EBMT Meeting Wien 2010 21-24 May, abstr 595.
58. Waller CF, Bronchud MH, Mair SJ, Challand R,. Bioequivalence of a biosimilar filgrastim and reference filgrastim: impact of the mobilization of CD34+ peripheral blood progenitor cells in a randomized, phase I study. 36° EBMT, Wien 2010 21-24 May, Abstr 1021.
59. Barosi G, Bosi A, Abbracchio MP, Danesi R, Genazzani A, Corradini P, Pane F, Tura S,. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2011; 96: 937-42.
60. Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P, Dumontel C, Moullet I, Eljaafari-Corbin A, Neidhardt-Berard M, Boufia F, Coiffer B,. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-55.
61. Weawer CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W,. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collection in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-9.
62. Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C, Kim S, Lee DH, Lee JS, Park CJ, Huh J, Suh C,. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion 2009; 49: 1890-900.
63. Gorin NC, Labopin M, Reiffers J, Blaise D, Witz F, de Witte T, Meloni G, Attal M, Bernal T, Rocha V,. Acute Leukemia Working Party; European Cooperatve Group for Blood and Marrow Transplantation. Higher incidence of relapse in patients with acute myeloid leukemia infused with higher doses of CD34+ cells from leukapheresis products during first remission. Blood 2010; 116: 3157-62.
64. Toro JJ, Morales M, Loberiza F, Ochoa-Bayona JL, Freytes CO,. Patterns of use of vascular access devices in patients undergoing hematopoietic stem cell transplantation: results of an international survey. Support Care Cancer 2007; 15: 1375-83.
65. Ravagnani F, Coluccia P, Notti P, Arienti F, Bompadre A, Avella M, Bozzi F, Barzanò E, Podda M, Pupa S, Luksch R,. Peripheral blood stem cell collection in pediatric patients: feasibility of leukapheresis under anesthesia in uncompliant small children with solid tumors. J Clin Apher 2006; 21: 85-91.
66. Moog R,. Peripheral blood stem cell collection in children: management, techniques and safety. Transfus Apher Sci 2010; 43: 203-5.
67. Bambi F, Fontanazza S, Messeri A, Lippi A, Tucci F, Tamburini A, Tintori V, Casini T, Lacitignola L, Tondo A, Veltroni M, Bernini G, Faulkner LB,. Use of percutaneous radial artery catheter for peripheral blood progenitor cell collection in pediatric patients. Transfusion 2003; 43: 254-8.
68. Sarcodee-Adoo C, Taran I, Guo C, Buadi F, Murthy R, Cox E, Lopez R, Westphal S, Shope S, O'Connell B, Wethers L, Meisenberg B,. Influence of preapheresis clinical factors on the efficiency of CD34+ cell collection by large-volume apheresis. Bone Marrow Transplant 2003; 31: 851-5.
69. Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Lansdorp PM, Bonadonna G, Gianni AM,. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-9.
70. Brando B, Barnett D, Janossy G, Mandy F, Autran B, Rothe G, Scarpati B, D'Avanzo G, D'Hautcourt JL, Lenkei R, Schmitz G, Kunkl A, Chianese R, Papa S, Gratama JW,. Cytofluorimetric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis. Cytometry 2000; 42: 327-46.
71. Chapple P, Prince HM, Wall D, Filshie R, Haylock D, Quinn M, Bretell M, Venter D,. Comparison of three methods of CD34+ cell enumeration in peripheral blood: dual-platform ISHAGE protocol versus single-platform microvolume fluorimetry. Cytotherapy 2000; 2: 371-6.
72. Gratama JW, Sutherland DR, Keeney M, Papa S,. Flow cytometry enumeration and immunophenotyping of hematopoietic stem and progenitor cells. J Biol Regul Homeost Agents 2001; 15: 14-22.
73. Sutherland DR, Nayyar R, Acton E, Giftakis A, Dean S, Mosiman VL,. Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCalbur and FACSCanto flow cytometers. Cytotherapy 2009; 11: 595-605.
74. Callera F, Cavenaghi L, De Melo CM,. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: a feasible strategy for multiple myeloma or pre-treated non-Hodgkin's lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF. Transfus Apher Sci 2009; 40: 91-5.
75. Elliott C, Samson DM, Armitage S, Lyttelton MP, McGuigan D, Hargreaves R, Giles C, Abrahamson G, Abboudi Z, Brennan M, Kanfer EJ,. When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. J Clin Oncol 1996; 14: 970-3.
76. Lane TA, Bashey A, Carrier E, Holman P, Castro J, Mullen M, Ward DM, Ada O, Ball ED,. Improving the efficiency of PBPC collection by pre-apheresis peripheral blood and mid-apheresis product measurements of CD34 cells. Cytotherapy 2004; 6: 318-27.
77. Szwajcer D, Jennings-Coutts A, Giftakis A, Wall DA,. Identification of the CD34 enumeration on the day before stem cell harvest that best predicts poor mobilization. Transfusion 2011; 51: 587-90.
78. Gutensohn K, Magens MM, Kuehnl P, Zeller W,. Increasing the economic efficacy of peripheral blood progenitor cell collections by monitoring peripheral blood CD34+ concentrations. Transfusion 2010; 50: 656-62.
79. Rhodes B, Anderlini P,. Allogeneic peripheral blood stem cell collection as of 2008. Transfus Apher Sci 2008; 38: 219-27.
80. Humpe A, Riggert J, Meineke I, Kurtz M, Eil A, Storkebaum B, Binder C, Munzel U, Funke I, Hocker P, Weisneth M, Kohler M,. A cell-kinetic model of CD34+ cell mobilization and harvest: development of a predictive algorithm for CD34+ cell yield in PBPC collections. Transfusion 2000; 40: 1363-70.
81. Pierelli L, Maresca M, Piccirillo N, Pupella S, Gozzer M, Foddai ML, Vacca M, Adorno G, Coppetelli U, Paladini U,. Accurate prediction of autologous stem cell apheresis yield using a double variable-dependent method assures systematic efficiency control of continuous flow collection procedures. Vox Sang 2006; 9: 126-34.
82. Ramakrishna LR,. Mobilization and collection of peripheral blood progenitor cells for transplantation. Transfus Apher Sci 2005; 32: 63-72.
83. Gasova Z, Marinov I, Vodvarkova S, Bohmova M, Bhuyian-Ludvikova Z,. PBPC collection techniques: standard versus large volume leukapheresis (LVL) in donors and patients. Transfus Apher Sci 2005; 32: 167-76.
84. Accorsi P, Dell'Isola M, Bonfini T, Giancola R, Spadano A, Fioritoni G, Iacone A,. Large volume leukapheresis with Amicus cell separator in peripheral blood stem cell autologous transplant. Transfus Apher Sci 2001; 24: 79-83.
85. Moller AK, Dickmeiss E, Geisler CH, Christensen LD,. Recruitment of CD34+ cell during large-volume leukapheresis. J Hematother Stem Cell Res 2001; 10: 837-53.
86. Bolan CD, Carter CS, Wesley RA, Yau YY, Barrett AJ, Childs RW, Read EJ, Leitman SF,. Prospective evaluation of cell kinetics, yields and donor experiences during a single large volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells. Br J Haematol 2003; 120: 801-7.
87. Morrison AE, Watson D, Buchanan S, Green RH,. Prospective randomised concurrent comparison of the COBE Spectra Version 4.7, COBE Spectra Version 6 (AutoPBSC) and Haemonetics MCS+ cell separators for leukapheresis in patients with haematological and non haematological malignancies. J Clin Apher 2000; 15: 224-9.
88. Ford CD, Lehman C, Strupp A, Kelley L,. Comparison of CD34+ cell collection efficiency on the COBE Spectra and Fenwal CS3000 Plus. J Clin Apher 2002; 17: 17-20.
89. Jeanne M, Bouzgarrou R, Lafarge X, Fizet D, Dazey B, Vezon G, Ivanovic Z,. Comparison of CD34+ cell collection on the CS-3000+ and Amicus blood cell separators. Transfusion 2003; 43: 1423-7.
90. Altuntas F, Kocygit I, Ozturk A, Kaynar L, Sari I, Oztekin M, Solmaz M, Eser B, Cetin M, Unal A,. Comparison of the Fenwal Amicus and Fresenius Com.Tec cell separators for autologous peripheral blood progenitor cell collection. Transfus Apher Sci 2007; 36: 159-67.
91. Orbach D, Hojjat-Assari S, Doz F, Pacquement H, Guillame A, Mathiot C, Zucker JM, Michon J,. Peripheral blood stem cell collection in 24 low-weight infants: experience of a single centre. Bone Marrow Transplant 2003; 31: 171-4.
92. Demirer T, Buckner CD, Bensinger WI,. Optimization of peripheral blood stem cell mobilization. Stem Cells 1996; 14: 106-16.
93. Mehan KR, Hill JM, Patchett L, Webber SM, Wu J, Ely P, Szcepiorkowsi ZM,. Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization. Transfusion 2006; 46: 523-9.
94. Roncon S, Barbosa IL, Campilho F, Lopes SM, Campos A, Carvalhais A,. Mobilization and collection of peripheral blood stem cells in multiple myeloma patients older than 65 years. Transplant Proc 2011; 43: 244-6.
95. Sinha S, Poh KK, Sodano D, Flanagan J, Ouilette C, Kearney M, Heyd L, Wollins J, Losordo D, Weinstein R,. Safety and efficacy of peripheral blood progenitor cell mobilization and collection in patients with advanced coronary heart disease. J Clin Apher 2006; 21: 116-20.